Dr. Lipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
# 320
Rochester, NY 14642Phone+1 585-275-5823Fax+1 585-273-1051- Is this information wrong?
Education & Training
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2005 - 2008
- Albany Medical CollegeClass of 2005
Certifications & Licensure
- NH State Medical License 2008 - Present
- NY State Medical License 2015 - 2025
- KS State Medical License 2011 - 2016
- VT State Medical License 2007 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Denosumab for Smoldering Multiple Myeloma Start of enrollment: 2019 Apr 19
- Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Roles: Contact, Principal Investigator
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Start of enrollment: 2023 Aug 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 21 citationsBisphosphonates for delivering drugs to boneShuting Sun, Jianguo Tao, Parish P. Sedghizadeh, Philip T. Cherian, Adam Junka
British Journal of Pharmacology. 2021-05-01 - 238 citationsInternational myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengass, Saad Z. Usmani, S. Vincent Rajkumar, Brian G.M. Durie, Maria-Victoria Mateos
The Lancet. Oncology. 2019-06-01 - 55 citationsConsensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.Noopur S Raje, Elias Anaissie, Shaji K Kumar, Sagar Lonial, Thomas Martin
The Lancet. Haematology. 2022-02-01
Abstracts/Posters
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based TherapyBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- Survivorship Plan for Multiple MyelomaDecember 3rd, 2022
- For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?December 1st, 2021
- Clinical Trials Gave Wilmot Multiple Myeloma Patient 18 Years - and He's Not Done CountingMay 20th, 2021
- Join now to see all
Hospital Affiliations
- Strong Memorial Hospital of the University of RochesterRochester, New York
- Canandaigua Veterans Affairs Medical CenterCanandaigua, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: